GlassScriptPhysician profile
David Samuel Prince
NPI 1447275698
$12,760.60
in general payments reported to CMS, 2019-2025
52 companies · $2,526 in 2025
The $2,526 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $399 · 2021: $542 · 2022: $2,096 · 2023: $2,424 · 2024: $3,242 · 2025: $2,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,010 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,010.49 |
| Education | $180.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,723.77 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,263.56 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,032.59 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Insmed, INC. | $1,011.39 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $639.62 | 2021-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $636.77 | 2020-2024 | Xarelto |
| Mylan Specialty L.P. | $593.62 | 2019-2024 | Yupelri |
| Genzyme Corporation | $391.20 | 2019-2025 | |
| Philips North America LLC | $383.53 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $369.65 | 2019-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $368.56 | 2022-2025 | Dupixent |
| United Therapeutics Corporation | $329.68 | 2021-2025 | Tyvaso, Tyvaso |
| Inspire Medical Systems, INC. | $296.05 | 2023-2025 | Inspire |
| Genentech USA, INC. | $284.04 | 2019-2024 | Xolair |
| Axsome Therapeutics, INC. | $267.40 | 2023-2025 | Sunosi |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $253.03 | 2021-2025 | Tezspire, Tavneos |
| Abbvie INC. | $216.17 | 2022-2025 | |
| Verona Pharma, INC. | $208.49 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $191.04 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Electromed, INC. | $190.31 | 2023-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $169.70 | 2020-2025 | Aralast |
| Pulmonx Corporation | $141.94 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $128.30 | 2024-2025 | Acthar |
| Amarin Pharma, INC. | $126.31 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $118.29 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $105.92 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $105.10 | 2023-2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $95.57 | 2019-2024 | Eliquis |
| Alexion Pharmaceuticals, INC. | $91.61 | 2021-2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $91.08 | 2022-2024 | Zerbaxa, Recarbrio |
| Vifor Pharma, INC. | $86.21 | 2024-2025 | Zemaira, Veltassa |
| Baxter Healthcare | $77.90 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Paratek Pharmaceuticals, INC. | $66.07 | 2020-2024 | Nuzyra |
| Jazz Pharmaceuticals INC. | $65.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.83 | 2023-2024 | |
| Resmed Corp | $62.48 | 2023-2025 | |
| Pfizer INC. | $59.22 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $58.84 | 2019 | |
| Astellas Pharma US INC | $48.93 | 2024 | Cresemba |
| Shionogi INC | $45.03 | 2025 | Fetroja |
| Sunovion Pharmaceuticals INC. | $41.31 | 2019 | |
| Zoll Respicardia, INC. | $37.40 | 2025 | Remede System |
| Abiomed | $35.42 | 2023 | Impella |
| Tactile Systems Technology INC | $35.16 | 2024 | Flexitouch Plus, Entre Plus |
| Phadia US INC. | $27.38 | 2019 | |
| La Jolla Pharmaceutical Company | $24.24 | 2024 | Giapreza |
| Idorsia Pharmaceuticals US INC | $22.30 | 2023 | Quviviq |
| Shire North American Group INC | $19.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.31 | 2025 | |
| Optinose US, INC. | $15.67 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2019 | |
| Allergan, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.